The present invention relates to chirally controlled oligonucleotides, chirally controlled
oligonucleotide compositions, and the method of making and using the same. The invention …

The present application, among other things, provides technologies, eg, reagents, methods,
etc. for preparing oligonucleotides comprising phosphorothiotriesters linkages, eg …

US9695211B2 - Method for the synthesis of phosphorus atom modified nucleic acids - Google
Patents US9695211B2 - Method for the synthesis of phosphorus atom modified nucleic acids …

Abstract Purpose: NY-ESO-1, one of the most immunogenic tumor antigens, is expressed in
15% to 25% of metastatic prostate cancers. The immunological and clinical effects of …

The magnitude and specificity of cell-mediated and humoral immunity are critically
determined by peptide sequences; peptides corresponding to the B-or T-cell receptor …

Cancer vaccine has the ability to directly eradicate tumor cells by creating and activating
cytotoxic T lymphocytes (CTLs). To achieve efficient CTL activity and to induce Th1 …

First generation Leishmania vaccines consisting of whole killed parasites with or without
adjuvants have reached phase 3 trial and failed to show enough efficacy mainly due to the …

2019-03-01 Assigned to WAVE LIFE SCIENCES LTD. reassignment WAVE LIFE SCIENCES
LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS) …

Solution The present invention relates to an adjuvant which com prises oligonucleotides
which comprise two to four sequences each represented by 5'-X, CpG X2-3'and has a length …

Abstract wherein each nucleic acid at 3′ end and 5′ end of the oligonucleotide is S type
nucleic acid connected by phosphorothioate linkage, and wherein the oligonucleotide …